Cryoablation Devices Market By Device Type (Cryoablation Systems, Cryoprobes, Gas Cylinders, Accessories & Consumables), By Application (Cardiovascular, Oncology, Pain Management, Dermatology, Gynecology, Others), By Technology (Tissue Contact Probes, Tissue Spray Probes, Cryogenic Gas-Based Systems, Liquid Nitrogen-Based Systems, Argon-Based Systems, Hybrid Cryoablation Systems), By Mode of Treatment (Percutaneous Ablation, Surgical Ablation, Endovascular Ablation), and By End User (Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, Cancer Treatment Centers, Cardiac Centers, Academic and Research Institutes), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

Industry Outlook

The Cryoablation Devices market accounted for USD 478.96 Million in 2024 and USD 544.67 Million in 2025 is expected to reach USD 1970.17 Million by 2035, growing at a CAGR of around 13.72% between 2025 and 2035. The cryoablation devices market specialises in medical devices involving the use of extreme low temperature to destroy malignant or diseased tissue, usually only applied in the treatment of cancer, cardiovascular diseases, and pain. These applicators utilise freezing as a medium of killing the targeted cells to death and yet not affecting the healthy body tissue. Systems incorporated in the market are of internal processes and external processes, including cryoprobes and cryoablation catheters. Increased cases of cancers, demand for minimally invasive treatment, and technological development are the major factors that promote growth in this sector. The crucial end-users include hospitals, ambulatory surgical centres, and specialised clinics.

Industry Experts Opinion

"The cryoSPHERE MAX probe reduces freeze times by up to 50 percent and improves tissue contact for post-operative nerve blocks—helping streamline procedures and enhance patient outcomes."

• Dr. Joseph Lamelas, Cardiothoracic Surgeon, University of Miami Health System

"An FDA advisory panel has endorsed ProSense® cryoablation as a viable less‑invasive option for select early-stage, low‑risk breast cancer patients, signifying a pivotal shift in standard care pathways."

• Dr. Richard Fine, Breast Surgeon at West Cancer Center

Report Scope:

Market Dynamics

Rising cancer prevalence increases demand for advanced treatment technologies.

The rise in the use of cryoablation equipment is mostly because people throughout the world are getting cancer. The World Health Organisation (WHO) reports that cancer caused close to 10 million deaths in 2020, thus making cancer one of the leading killers globally. In the United States, the Centres for Disease Control and Prevention (CDC) recorded up to 1.6 million cases diagnosed with cancer and over 600,000 deaths in 2022.

Cryoablation is an emerging form of cancer therapy that kills the cancerous tissue using extreme low temperature instead of surgery, and it is becoming increasingly popular in the treatment of cancer patients who carry tumours in the liver, kidney, and lungs. It is also effective and has a shorter recovery period, which is why it is popular in clinical practice and especially among old or delicate patients.

There is also an increase in the number of ageing populations and national screening programmes, including the NHS Cancer Screening Programme in the UK, which are facilitating the discovery of tumours at an earlier stage and thus are providing more opportunities in terms of early-stage cryoablation interventions in cancer and the ability to manage it.

Technological advancements improve precision and efficacy of cryoablation systems.

Technological progress that makes cryoablation devices more accurate, safer for patients, and more effective is one of the things that drives the industry. Owing to a combination of real-time imaging, miniaturised cryoprobes, and automated real-time systems, there has been increased accuracy and efficacy in cryoablation procedures, which makes it a more viable treatment to treat several conditions, such as cancer and cardiac arrhythmias. An increase in the rate of prevalence of these diseases is another contributor to demand. The CDC notes that heart disease is the number one killer in the U.S., with approximately 695,000 people dying of the condition every year.

The National Cancer Institute (NCI) estimated 1.9 million new diagnosed cancer cases in 2024 in the U.S. Minimally invasive techniques such as cryoablation have the benefit of decreased recovery periods and the reduced rate of complications, which fits the purpose of healthcare to limit the length of hospital stay and expenditures. Market expansion is aided by the increased number of the geriatric population, which is more susceptible to developing chronic diseases, and favourable regulatory systems.

High cost of devices limits access in developing regions.

In the cryoablation devices market, the high cost of equipment and procedures is one of the critical constraints, especially in developing areas. Such machines usually need a sophisticated infrastructure and skilled doctors who are not available in low-income and middle-income nations. The World Health Organisation (WHO) estimates that more than 50% of the world population do not have essential health services, and the gap is most pronounced in sub-Saharan Africa and some parts of South Asia.

Further World Bank statistics indicate that in most of the developing countries, the per capita expenditure on health is lower than 100 dollars per year. It would be impossible to implement such high-cost medical interventions as cryoablation. Institutions that are public hospitals in such areas mostly focus on the normal health needs rather than special measures like tumour ablation. Such an economic barrier both restricts the applicability and the knowledge of the cryoablation technologies, which cannot be expected to expand the market in the sphere effectively, even with their current increased global need for cancer treatment.

Expanding geriatric population fuels need for effective ablation therapies.

With the growing geriatric population comes the growing need for effective but minimally invasive procedures such as cryoablation in treating patients, especially in cases of cancer and cardiac arrhythmias. Older people are more liable to have chronic ailments which would need to be treated, and cryoablation is a safer alternative to any open surgery and has fewer complications and shorter healing periods. The United Nations projects the number of people aged 65 and older to be 761 million in 2021 worldwide.

According to the Centres for Disease Control and Prevention (CDC), approximately 80 per cent of older adults have at least one chronic condition, and 68% have two or more. These data will highlight why there is a demand for newer, less invasive methods of treatment. Since healthcare units are focusing on the safety of the patients and cost-effectiveness, there is a strong possibility that cryoablation devices fit these needs in any ageing population across the globe.

Integration with imaging technologies enhances treatment planning and outcomes.

The adoption of imaging techniques, including MRI, CT, and ultrasound, has contributed greatly toward the accuracy and effectiveness of cryoablation procedures in the management of cancers like renal cell carcinoma and prostate cancer. Scholarly research and works indicate that the ability to plan cryoablation with 3D imaging has the potential to increase the placement accuracy of probes and decrease the likelihood of residual tumours occurring in locations that were not detected because of the inaccurate probe placement.

The study has shown that less than 5% of patients with small renal tumours suffered any local recurrence when they had been subjected to imaging-guided cryoablation as a form of treatment, according to the Journal of Urology. The National Cancer Institute also makes an observation that image-guided ablation methods have become a kind of norm among patients who cannot bear surgery operations, which drives an ever-increasing need for even more integrated cryoablation systems.

The trend explains a good market potential of unity of cryoablation devices by creating or incorporating devices with embedded imaging capabilities that resulted in better clinical results and minimising complications, especially when such devices are used to deliver minimally invasive oncology treatment.

Segment Analysis

Based on the Device type, the Cryoablation Devices market is classified into Cryoablation Systems, Cryoprobes, Gas Cylinders, Accessories & Consumables. The dominant type of device in the cryoablation devices market is the cryoprobe. Cryoprobes are necessary in oncological procedures and cardiovascular procedures, as they are important in ensuring that the freezing part is done accurately and on the specific tissues. This leads to high demand because of their wide use in the treatment of tumours, most especially in kidney, prostate, and liver cancers. Their effectiveness, safety, and imaging compatibility with systems and safety have increased due to technological developments, and this has further enhanced their adoption. Cryoprobes have the greatest market share and are our system's core functional component of the cryoablation system, and subsequent probes are the key to the success of a procedure.

Based on the application, the Cryoablation Devices market is classified into Cardiovascular, Oncology, Pain Management, Dermatology, Gynecology, and Others. The biggest and most dominant application in the cryoablation devices market is oncology. Various cancers, such as liver, kidney, prostate, and lung cancers, are among the types of malignancies that are treated through cryoablation since the treatment is known to be non-invasive and also very accurate when it comes to the destruction of malignant cells but sparing healthy ones. This market is highly demanded due to the increasing cancer rate globally and the preference for less invasive treatment methods. Moreover, ever-increasing technological changes and clinical success contribute to the leading role of oncology in the cryoablation market.

Regional Analysis

The North America Cryoablation Devices Market is expanding due to the rising prevalence of chronic diseases that may be treated effectively with the help of minimally invasive procedures, including cardiac arrhythmias, prostate cancer, and other types of tumours. The presence of well-developed health infrastructure, growing use of new technologies in cryoablation, and positive trends in reimbursements can be discussed as factors improving the market growth.

The presence of considerable research and development by major medical device companies and increasing knowledge of physicians and patients on the superiority of cryoablation over conventional surgical processes have helped the region. Moreover, relevant stakeholders are supporting market demand growth due to the rising number of older persons and the growing outpatient procedures.

The U.S. market is a monopoly, as the country is well-developed in the field of healthcare services and spends more on high-tech medical aid. Nevertheless, some barriers like the price of devices and the need for specific training could slightly hinder the fast growth in small healthcare facilities. Overall, the North American market has potential as the technologies are progressing, and the sphere of clinical applications continues to grow.

The Asia Pacific cryoablation devices market is growing extensively due to the rising cases of cancer and cardiovascular diseases in this region. An increase in awareness of the use of minimally invasive treatment options, as well as the developing infrastructure of healthcare in countries such as China, Japan, or India, currently stimulates demand.

The market is also expanding due to increasing government efforts and investments in modern technologies in the field of medicine. There are also high numbers of patients in the region and developing medical tourism, which favours the adoption of cryoablation therapies. Nevertheless, there are still problems with limited competent professionals and expensive prices. In general, the Asia Pacific market demonstrates the potential for successful growth, as constant innovations and active healthcare spending are likely to promote development in the following years.

Competitive Landscape

The cryoablation devices market is very competitive, where the main players are Medtronic, Boston Scientific, Johnson & Johnson, Abbott Laboratories, and Siemens Healthineers. These firms are still advancing by increasing indications and device precision, especially in the cardiology and cancer fields. In the recent past, Medtronic has engaged in the improvement of its catheter designs to achieve a better level of safety and efficacy of the procedures, and Boston Scientific has been busy diversifying its cryoablation platform in arrhythmia therapy.

New entrants such as IceCure Medical and Metrum Cryoflex are taking off by offering low-invasive devices that address ultra-specific clinical interests. There is the collusion and strategic buy-outs, where firms find the need to enhance their technologies to improve technological capacities and geographical coverage. The level of focus on the combination of real-time imaging and navigation technologies to streamline the ablation is also growing in the market, as there is a constant concern regarding increased patient care and a high rate of procedural success.

Cryoablation Devices Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Recent Developments:

• In February 2025, IceCure submitted its next-generation XSense™ cryoablation system and cryoprobes for Israeli regulatory approval. The submission covered a wide range of surgical uses, from general to cancer-related procedures. This built on their existing FDA clearances for the ProSense® system. The move aimed to expand their product availability and applications.

Report Coverage:

By Device Type

• Cryoablation Systems
• Cryoprobes
• Gas Cylinders
• Accessories & Consumables

By Application

• Cardiovascular
• Oncology
• Pain Management
• Dermatology
• Gynecology
• Others

By Technology

• Tissue Contact Probes
• Tissue Spray Probes
• Cryogenic Gas-Based Systems
• Liquid Nitrogen-Based Systems
• Argon-Based Systems
• Hybrid Cryoablation Systems

By Mode of Treatment

• Percutaneous Ablation
• Surgical Ablation
• Endovascular Ablation

By End User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics
• Cancer Treatment Centers
• Cardiac Centers
• Academic and Research Institutes

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Medtronic plc
• Boston Scientific Corporation
• Johnson & Johnson
• Abbott Laboratories
• Siemens Healthineers AG
• GE Healthcare
• Varian Medical Systems Inc.
• CooperSurgical Inc.
• MicroPort Scientific Corporation
• AtriCure Inc.
• IceCure Medical Ltd.
• Hologic Inc.
• BVM Medical Limited
• CPSI Biotech
• Metrum Cryoflex

Frequently Asked Questions (FAQs)